Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

被引：0
|
作者：
McGuire, D. K. [1 ]
Rosenstock, J. [2 ]
Johansen, O. E. [3 ]
Zinman, B. J. [4 ]
Khunti, K. [5 ]
Mattheus, M. [6 ]
Lund, S. S. [3 ]
Espeland, M. A. [7 ]
Marx, N. [8 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Dallas Diabet Res Ctr Med City, Dallas, TX USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Univ Hlth Network, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada
[5] Univ Leicester, Leicester, Leics, England
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[7] Wake Forest Univ, Winston Salem, NC 27101 USA
[8] RWTH Univ Hosp Aachen, Aachen, Germany
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3356 / 3356
页数：1
相关论文
共 50 条
  • [21] Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial
    Muskiet, Marcel H. A.
    Tonneijck, Lennart
    Smits, Mark M.
    Kramer, Mark H. H.
    Ouwens, D. Margriet
    Hartmann, Bolette
    Holst, Jens J.
    Danser, A. H. Jan
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 115 - 124
  • [22] Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial
    Muskiet, Marcel H. A.
    Tonneijck, Lennart
    Smits, Mark M.
    Kramer, Mark H. H.
    Ouwens, D. Margriet
    Hartmann, Bolette
    Holst, Jens J.
    Touw, Daan J.
    Danser, A. H. Jan
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETES CARE, 2020, 43 (11) : 2889 - 2893
  • [23] Latin American clinical trial project on insulin glargine versus NPH insulin plus glimepiride in Type 2 diabetes.
    Eliaschewitz, FG
    Calvo, C
    Valbuena, H
    Ruiz, M
    Aschner, P
    Villena, J
    Ramirez, LA
    Jimenez, J
    Macêdo, M
    DIABETOLOGIA, 2003, 46 : A272 - A272
  • [24] CARMELINA® Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk
    Rosenstock, Julio
    Perkovic, Vlado
    Alexander, John H.
    Cooper, Mark Emmanuel
    Kahn, Steven E.
    Marx, Nikolaus
    Pencina, Michael J.
    Toto, Robert D.
    Wanner, Christoph
    Zinman, Bernard
    Baanstra, David
    Pfarr, Egon
    Mattheus, Michaela
    George, Jyothis T.
    Broedl, Uli C.
    Woerle, Hans-Juergen
    Von Eynatten, Maximilian
    Mcguire, Darren K.
    DIABETES, 2017, 66 : A344 - A344
  • [25] CARMELINA® trial baseline characteristics: a cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk
    Perkovic, V.
    Rosenstock, J.
    MacGuire, D. K.
    DIABETOLOGIA, 2017, 60 : S357 - S357
  • [26] A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy
    Yu, Hea Min
    Kim, Sang Jin
    Chun, Sung Wan
    Park, Keun Young
    Lim, Dong Mee
    Lee, Jong Min
    Hong, Jun Hwa
    Park, Kang Seo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 155
  • [27] 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
    Gallwitz, Baptist
    Rosenstock, Julio
    Rauch, Thomas
    Bhattacharya, Sudipta
    Patel, Sanjay
    von Eynatten, Maximilian
    Dugi, Klaus A.
    Woerle, Hans-Juergen
    LANCET, 2012, 380 (9840): : 475 - 483
  • [28] Disparate effects of the combined therapy of empagliflozin and linagliptin versus metformin and insulin glargine on renal haemodynamics in type 2 diabetes
    Ott, C.
    Jung, S.
    Kannenkeril, D.
    Striepe, K.
    Bosch, A.
    Korn, M.
    Bramlage, P.
    Schmieder, R. E.
    DIABETOLOGIA, 2019, 62 : S40 - S40
  • [29] The effects of pioglitazone vs glimepiride on adipose tissue distribution in patients with type 2 diabetes: results from the CHICAGO Trial
    Davidson, M.
    D'Agostino, R., Sr.
    Feinstein, S.
    Haffner, S.
    Kondos, G.
    Meyer, P.
    Perez, A.
    Mazzone, T.
    DIABETOLOGIA, 2007, 50 : S357 - S357
  • [30] Vildagliptin versus insulin as add-on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled trial
    Strotmann, H. -J.
    Goetze, D.
    Koch, C.
    Forst, T.
    DIABETOLOGIA, 2014, 57 : S364 - S365
12345